1 research outputs found
Engineering an Fc-Fusion of a Capsule Degrading Enzyme for the Treatment of Anthrax
Polymers of d-glutamic acid (PDGA) form the
capsule of
the highly virulent Ames strain of B. anthracis. PDGA is antiphagocytic and weakly immunogenic; it enables the bacteria
to evade the innate immune responses. CapD is an enzyme that catalyzes
the covalent anchoring of PDGA. CapD is an Ntn-amido hydrolase that
utilizes an internal Thr-352 as its nucleophile and general acid and
base. An internal cleavage produces a free N-terminal Thr-352 and
a short and long polypeptide chain. The chains were circularly permuted
(CP) to move Thr-352 to the N-terminus of the polypeptide. We previously
showed that a branched PEG-CapDS334C-CP could protect mice
(80% survival) against a 5 LD50 challenge with B. anthracis Ames without the use of antibiotics, monoclonals,
or vaccines. In attempts to improve the in vivo circulation
time of CapD and enhance its avidity to its polymeric substrate, an
Fc-domain of a mouse IgG1 was fused to CapDS334C-CP and
the linker length and sequence were optimized. The resulting construct,
Fc-CapDS334C-CP, then was pegylated with a linear 2 kDa
mPEG at S334C to produce mPEG-Fc-CapDS334C-CP. Interestingly,
the fusion of the Fc-domain and incorporation of the S334C mutation
imparted acid stability, but slightly reduced the kcat (∼ 2-fold lower). In vivo,
the measured protein concentration in sera was higher for the Fc-fusion
constructs compared to the mPEG-Fc-CapDS334C-CP. However,
the exposure calculated from measured sera enzymatic activity was
higher for the mPEG-CapDS334C-CP. The pegylated Fc-fusion
was less active than the PEG-CapDS334C-CP, but detectable
in sera at 24 h by immunoblot. Here we describe the engineering of
a soluble, active, pegylated Fc-fusion of B. anthracis CapD (mPEG-Fc-CapD-CP) with activity in vitro,
in serum, and on encapsulated bacteria